Ad hoc announcement pursuant to Art. 53 LR

Fribourg, 3 November 2025

AEVIS VICTORIA SA (AEVS.SW) – Continued revenue growth in the third quarter of 2025

Consolidated growth of 18.2%, driven by the Healthcare and Hospitality divisions. Adjusted organic growth of 2.6%.

AEVIS VICTORIA SA (AEVIS) achieved consolidated gross revenue of CHF 899.2 million in the first nine months of 2025, compared to CHF 761.0 million in the same period of 2024, representing total growth of 18.2%. Net revenue amounted to CHF 789.9 million (3Q2024: CHF 668.6 million), up 18.1%, including adjusted organic growth of 1.5%.

Healthcare: sustained growth and successful integration of new entities
With its 21 hospitals and its outpatient centers, Swiss Medical Network generated gross revenue of CHF 722.6 million (3Q2024: CHF 594.9 million), up 21.5%. Adjusted organic growth reached 3.3%, supported by the expansion of the outpatient network and the full integration of Spital Zofingen, CentroMedico in Ticino, and several medical practices in German-speaking Switzerland. Swiss Medical Network is continuing its expansion in integrated care, with the extension of the integrated care model to a third region, Aare Netz – the first in German-speaking Switzerland – on 1 January 2026.

Viva Health: Attractive premiums in all cantons within the integrated care regions
VIVA Health, the alternative basic insurance product developed in collaboration with insurer Visana, is entering its third year with the lowest premiums on the market in most categories and cantons. Viva is available in the Jura Arc, Ticino, and Zofingen/Aarau regions.

Hospitality: positive momentum maintained
MRH Switzerland AG, the group’s hotel division managed by Michel Reybier Hospitality, generated gross revenue of CHF 157.4 million (3Q2024: CHF 151.6 million), up 3.8%. Organic growth was supported by excellent performance across all establishments. The winter season, starting on 12 December 2025, looks promising, as Switzerland continues to strengthen its appeal as a travel destination. The hotel portfolio has remained unchanged at eleven properties.

Real Estate: strong contribution driven by apartment sales in Zermatt
The Real Estate division, represented by Swiss Hotel Properties SA, recorded revenue of CHF 36.1 million (3Q2024: CHF 24.0 million), up 50.5%. This increase was mainly due to the sale of apartments in Zermatt, around one-third of which have already been sold. The remaining units will be marketed by the end of the winter season (1Q2026), further supporting the division’s revenue in the next quarter.

Strategic options under review
AEVIS VICTORIA is currently exploring various strategic options for its subsidiaries, particularly Swiss Medical Network and Infracore, to support their long-term development. Swiss Medical Network aims to cover all regions where it operates with its integrated care offering and with Viva, the alternative basic insurance product developed with Visana. In this context, AEVIS plans to welcome new strategic shareholders and intends to reduce its participation in Swiss Medical Network in order to strengthen the independence of the Swiss integrated care group. In parallel, Infracore is exploring various opportunities to open up its capital base, potentially including a listing, to meet the growing demand for sale-and-leaseback solutions in the public and private hospital market in Switzerland.

For further information:
AEVIS VICTORIA SA Media and Investor Relations: c/o Dynamics Group, Zurich
Philippe R. Blangey, prb@dynamicsgroup.ch, +41 (0) 43 268 32 35 or +41 (0) 79 785 46 32
Séverine Van der Schueren, svanderschueren@aevis.com, +41 (0) 79 635 04 10

AEVIS VICTORIA SA – Investing for a better life
AEVIS VICTORIA SA invests in healthcare, hospitality & lifestyle and infrastructure. AEVIS′s main shareholdings are Swiss Medical Network Holding SA (76.3%, directly and indirectly), the only Swiss private network of hospitals present in the country’s three main language regions, MRH Switzerland AG, a luxury hotel group managing eleven hotels in Switzerland and abroad, Infracore SA (30%, directly and indirectly), a real estate company dedicated to healthcare-related infrastructure, Swiss Hotel Properties SA, a hospitality real estate division, and NESCENS SA, a brand dedicated to better aging. AEVIS is listed on the Swiss Reporting Standard of the SIX Swiss Exchange (AEVS.SW).
www.aevis.com.

STRATEC REPORTS SUPPLY CHAIN-RELATED PRODUCTION DELAYS, ADJUSTMENT TO 2025 SALES GUIDANCE AND PRELIMINARY RESULTS FOR 9M/2025

Birkenfeld, October 30, 2025

STRATEC SE, Birkenfeld, Germany (Frankfurt: SBS; Prime Standard, SDAX), expects to witness temporary interruptions to the supply of input materials for some of its system lines in the fourth quarter of 2025. In particular, in connection with trade policy tensions a supply chain interruption has arisen in recent weeks for a specific type of magnet with impurities relating to export-restricted rare earths (0.1% share of affected production batch). Against this backdrop, delivery backlogs already arose for system deliveries in the third quarter of 2025. Following close communication with its suppliers, STRATEC now no longer expects to receive sufficient quantities of input materials to make up for these delivery backlogs or for the production volumes originally planned for the fourth quarter of 2025. Furthermore, global tariff conflicts are leading to greater fluctuations in customers’ order behavior and to associated inventory optimization measures. These particularly affect the Service Parts and Consumables business.

In view of these factors, the Board of Management has decided to adjust its sales guidance for the 2025 financial year. STRATEC now expects its consolidated sales at constant currency to approximately match the previous year’s figure (previously: “consolidated sales at constant currency to show growth in a low to medium single-digit percentage range”). Despite the lower sales base hereby forecast and negative currency items, STRATEC nevertheless expects to achieve the lower end of the forecast corridor of around 10.0% to 12.0% for its adjusted EBIT margin. This expected intra-year rise in profitability in the fourth quarter of 2025 is attributable to benefits of scale, efficiency measures, and higher earnings contributions from the realization of high-margin development sales.

Based on preliminary figures and despite the delivery backlogs that have already arisen, in the first nine months of 2025 STRATEC was able to increase its consolidated sales at constant currency year-on-year by 2.5% to € 175.6 million (9M/2024: € 173.0 million). The adjusted EBIT margin for the first nine months is expected to amount to 7.3% (9M/2024: 8.8%).

STRATEC will publish its definitive results and its Quarterly Statement for the first nine months of 2025 as planned on November 7, 2025.

FURTHER INFORMATION IS AVAILABLE FROM:
STRATEC SE
Jan Keppeler, CFA | Investor Relations, Sustainability & Corporate Communications
Tel: +49 7082 7916-6515
ir@stratec.com
www.stratec.com

Not for release, publication or distribution, directly or indirectly, in or intothe United States of America, Australia, Canada or Japan or any otherjurisdiction in which such release, publication or distribution would be unlawful. The important notes at the end of this announcement need to be observed.

• Revenue up 148% to EUR 75 million in the first nine months of 2025
• On track to become a European player – market liberalization in other European countries offers opportunities
• Outlook – Focus on further growth and geographic diversification

Berlin, 30 October 2025 – Cantourage Group SE continued its positive business development in the third quarter of 2025 and consolidated its position as one of the leading players in the European medical cannabis market, despite a challenging regulatory environment in Germany.

In the third quarter of 2025, Cantourage generated revenue of around EUR 20.1 million (comparable period 2024: EUR 13.2 million). This resulted in total group revenue of around EUR 74.9 million at the end of the third quarter (comparable period 2024: EUR 30.2 million). EBITDA of roughly EUR 3.9 million (comparable period in 2024: EUR 2.1 million) at the end of Q3 2025 underscores the strong operating performance and high scalability of the business model.

Robust development in Germany

In Germany, Cantourage recorded a robust development in both the cannabis flower and pharmaceutical ingredient business. Cantourage was able to further consolidate its position and successfully meet the demand for high-quality medical cannabis products.

“Germany remains a challenging market in a difficult regulatory and economic environment. Despite the current positive development, we are monitoring the broader conditions with due attention,” says Philip Schetter, CEO of Cantourage Group SE.

Growth in international markets

Cantourage is also continuing its growth trajectory outside Germany: positive momentum is continuing in the UK, while business is being expanded in a strategic approach in Poland. At the same time, Cantourage is preparing to enter other European growth markets such as Spain and Italy in order to benefit from the opening of these markets at an early stage.

Innovation and digitalization

Cantourage is continuing to develop its telemedicine offering in Germany in anticipation of regulatory changes, so that patients will continue to have the best possible and safe access to medical cannabis in the future. At the same time, the company is working on the development of new, innovative product formats that are designed to better meet the needs of patients.

Outlook

Against the backdrop of its operational performance to date in 2025, Cantourage is confident about the fourth quarter and the full year 2025. The company considers itself well positioned to achieve further growth in existing and new markets, but remains attentive to potential market changes. Note:

All figures are preliminary, unaudited, and unconsolidated.

About Cantourage
Cantourage is a leading European producer and distributor of cannabis flowers and cannabis-based medicinal preparations and drugs. The Berlin-based company was founded in 2019 by industry pioneers Norman Ruchholtz, Dr. Florian Holzapfel and Patrick Hoffmann. With an experienced management team and its “Fast Track Access” platform, Cantourage enables producers from around the world to become part of the growing European medical cannabis market faster, easier and more cost-effectively by processing and distributing their cannabis raw materials and extracts. In this context, Cantourage ensures compliance with the highest European pharmaceutical quality standards at all times. The company offers pharmaceutical-grade products in all relevant market segments: dried flower, extracts, dronabinol and cannabidiol. Cantourage was listed on the Frankfurt Stock Exchange on 11 November 2022 and is listed under – ISIN: DE000A3DSV01. 

Further information: www.cantourage.com

Investor Relations contact at Cantourage

Manuel Taverne
taverne@cantourage.com

This announcement does not constitute a public offer or an advertisement for a public offer to sell securities, in particular not within the meaning of Regulation (EU) 2017/1129 (Prospectus Regulation).

News Release

Notice of the Revised Forecast of Consolidated Financials for FY2025 (IFRS)

OSAKA, Japan, October 30, 2025 – Takeda (TSE:4502/NYSE:TAK) today announced the revised forecast of the full year consolidated financials for the fiscal year ending March 31, 2026 (FY2025), as below.

Takeda’s fiscal year 2025 first half results are consistent with our expectations for core business progress in this year of transition to a new phase focusing on new product launches. Our updated full-year outlook reflects impairment charges associated with strategic pipeline decisions taken in Q2, as well as transactional FX.

1. Revised Forecast for Full Year Consolidated Financials for the Fiscal Year Ending March 31, 2026

(millions JPY)

^* Announced on May 8, 2025.

(millions JPY)

^* Announced on May 8, 2025.

(Note) For the definition of Core financial measures, please refer to the “Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations” in the Financial Appendix attached to the Earnings Report.

2. Reasons for Revision

Takeda expects FY2025 revenue to be JPY 4,500.0 billion, a decrease of JPY 30.0 billion, or 0.7%, from the original forecast, mainly reflecting a revised forecast for ENTYVIO and a steeper than anticipated decline in VYVANSE sales in the U.S. due to generic erosion. These factors are partially offset by favorable overall changes in the assumptions of foreign exchange rates.

The Core Revenue forecast has been revised in the same way as the Revenue forecast.

Operating Profit is expected to decrease by JPY 75.0 billion, or 15.8%, from the original forecast to JPY 400.0 billion, primarily due to an unfavorable product mix as a result of lower revenue from high margin products, headwinds from transactional foreign exchange rates for certain products, and an increased forecast of impairment losses on intangible assets associated with products. These factors are expected to be partially offset by additional cost savings within R&D, including from pipeline prioritization and the enterprise-wide efficiency program, with such savings anticipated to broadly materialize as reductions in operating expenses.

Core Operating Profit is expected to be JPY 1,130.0 billion, a decrease of JPY 10.0 billion, or 0.9%.

Net Profit for the Year (attributable to owners of the Company) is expected to be JPY 153.0 billion, a decrease of JPY 75.0 billion, or 32.9%, from the original forecast. Profit Before Tax is expected to decrease by JPY 64.0 billion, or 20.8%, to JPY 243.0 billion, primarily due to the decrease in Operating Profit, while net finance expenses are expected to decrease by JPY 11.0 billion, or 6.6%, to JPY 156.0 billion. While Profit Before Tax is expected to decrease, the tax expense is anticipated to remain at a similar level to the original forecast due to an increase of non-deductible expenses mainly from impairments as well as derecognition of deferred tax assets, resulting in an assumed effective tax rate of approximately 37%.

Reported EPS is expected to be JPY 97.14, a decrease of JPY 47.66, or 32.9%, and Core EPS is expected to be JPY 479, a decrease of JPY 6, or 1.2%.

3. Management Guidance for the Fiscal Year Ending March 31, 2026

Takeda uses change in Core Revenue, Core Operating Profit and Core EPS at Constant Exchange Rate (CER) basis as its Management Guidance. The full year management guidance for the fiscal year ending March 31, 2026 (FY2025) has been revised from the management guidance announced on May 8, 2025.

CER % Change

About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.

Contacts

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this press release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

The product names appearing in this document are trademarks or registered trademarks owned by Takeda, or their respective owners.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects”, “forecasts”, “outlook” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States and with respect to international trade relations; competitive pressures and developments; changes to applicable laws and regulations, including tax, tariff and other trade-related rules; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals; the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits; and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/or at www.sec.gov.Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

Financial Information and Non-IFRS Measures

Takeda’s financial statements are prepared in accordance with International Financial Reporting Standards (“IFRS”).

This press release and materials distributed in connection with this press release include certain financial measures not presented in accordance with IFRS, such as Core Revenue, Core Operating Profit, Core Net Profit for the year attributable to owners of the Company, Core EPS, Constant Exchange Rate (“CER”) change, Net Debt, Adjusted Net Debt, EBITDA, Adjusted EBITDA, Free Cash Flow and Adjusted Free Cash Flow. Takeda’s management evaluates results and makes operating and investment decisions using both IFRS and non-IFRS measures included in this press release. These non-IFRS measures exclude certain income, cost and cash flow items which are included in, or are calculated differently from, the most closely comparable measures presented in accordance with IFRS. Takeda’s non-IFRS measures are not prepared in accordance with IFRS and such non-IFRS measures should be considered a supplement to, and not a substitute for, measures prepared in accordance with IFRS (which we sometimes refer to as “reported” measures). Investors are encouraged to review the definitions and reconciliations of non-IFRS measures to their most directly comparable IFRS measures, which are in the Financial Appendix appearing at the end of our FY2025 H1 investor presentation (available at www.takeda.com/investors).

###

Press Release // October 30, 2025
 

Formycon invites to Conference Call on 2025 Nine-Month Results and announces Participation in Investor Conferences in the 4th Quarter of 2025
 

Planegg-Martinsried, Germany – Formycon AG (FSB: FYB, Prime Standard, „Formycon“) plans to publish its Nine-Month Results 2025 on November 13, 2025. The Management Board will discuss the company’s development, key financial figures, and provide an outlook for the course of 2025. The conference call, which will be broadcast live on the internet, will take place on Thursday, November 13, 2025, at 3:00 PM (CET) in English.

To participate in the conference call, please register at:
https://webcast.meetyoo.de/reg/KYTa1G3ju56X

After registration, participants will receive a confirmation email with individual dial-in data.

The presentation and audio broadcast can be accessed via the following webcast link:
https://www.webcast-eqs.com/formycon-2025-q3

After a brief presentation, the Management Board will be available for analysts’ questions. The conference call will be recorded and can subsequently be accessed via the Formycon website at: https://www.formycon.com/en/investor-relations/publications/

Formycon in Dialogue

Representatives of the Management Board will participate in the following national and international investor conferences in the fourth quarter of 2025:

October 30, 2025
ODDO BHF Autumn Round Table
Dr. Stefan Glombitza (CEO)
Frankfurt, Germany

November 17 – 20, 2025
Jefferies Global Healthcare Conference
Enno Spillner (CFO)
London, UK

November 24 – 26, 2025
Deutsche Börse Equity Forum
Enno Spillner (CFO)
Frankfurt, Germany

December 9, 2025
mwb Research Roundtable
Dr. Stefan Glombitza (CEO), Enno Spillner (CFO),
Nicola Mikulcik (CBO), Dr. Andreas Seidl (CSO)
virtual

Preview on 2026:

January 12 – 15, 2026
J.P. Morgan 44^th Annual Healthcare Conference
Dr. Stefan Glombitza (CEO), Enno Spillner (CFO), Nicola Mikulcik (CBO)
San Francisco, USA
 

Please find our current events at:
https://www.formycon.com/en/investors/financial-calendar/

—————
 

About Formycon:
Formycon AG (FSE: FYB) is a leading, independent developer of high-quality biosimilars, follow-on products of biopharmaceutical medicines. The company focuses on therapies in ophthalmology, immunology, immuno-oncology and other key disease areas, covering almost the entire value chain from technical development through clinical trials to approval by the regulatory authorities. For commercialization of its biosimilars, Formycon relies on strong, well-trusted and long-term partnerships worldwide. With FYB201/ranibizumab and FYB202/ustekinumab, Formycon already has two biosimilars on the market. Another biosimilar, FYB203/aflibercept, has been approved by the FDA, EMA, and MHRA. Four pipeline candidates are currently in development. With its biosimilars, Formycon is making an important contribution to providing as many patients as possible with access to highly effective and affordable medicines.

Formycon AG is headquartered in Munich, listed in the Prime Standard of the Frankfurt Stock Exchange: FYB / ISIN: DE000A1EWVY8 / WKN: A1EWVY and is part of the SDAX selection index. Further information can be found at: https://www.formycon.com/

About Biosimilars:
Since their introduction in the 1980s, biopharmaceutical drugs have revolutionized the treatment of serious and chronic diseases. By 2032, many of these drugs will lose their patent protection – including 45 blockbusters with an estimated total annual global turnover of more than 200 billion US dollars. Biosimilars are successor products to biopharmaceutical drugs for which market exclusivity has expired. They are approved in highly regulated markets such as the EU, the USA, Canada, Japan and Australia in accordance with strict regulatory procedures. Biosimilars create competition and thus give more patients access to biopharmaceutical therapies. At the same time, they reduce costs for healthcare systems. Global sales of biosimilars currently amount to around 21 billion US dollars. Analysts assume that sales could rise to over 74 billion US dollars by 2030.

Contact:
Sabrina Müller
Director Investor Relations & Corporate Communications
Formycon AG
Fraunhoferstr. 15
82152 Planegg-Martinsried
Germany

Tel.: +49 (0) 89 – 86 46 67 149
Fax: + 49 (0) 89 – 86 46 67 110
Mail: Sabrina.Mueller@formycon.com

Disclaimer:
This press release may contain forward-looking statements and information which are based on Formycon’s current expectations and certain assumptions. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, performance of the company, development of the products and the estimates given here. Such known and unknown risks and uncertainties comprise, among others, the research and development, the regulatory approval process, the timing of the actions of regulatory bodies and other governmental authorities, clinical results, changes in laws and regulations, product quality, patient safety, patent litigation, contractual risks and dependencies from third parties. With respect to pipeline products, Formycon AG does not provide any representation, warranties or any other guarantees that the products will receive the necessary regulatory approvals or that they will prove to be commercially exploitable and/or successful. Formycon AG assumes no obligation to update these forward-looking statements or to correct them in case of developments which differ from those anticipated. This document neither constitutes an offer to sell nor a solicitation of an offer to buy or subscribe for securities of Formycon AG. No public offering of securities of Formycon AG will be made nor is a public offering intended. This document and the information contained therein may not be distributed in or into the United States of America, Canada, Australia, Japan or any other jurisdictions, in which such offer or such solicitation would be prohibited. This document does not constitute an offer for the sale of securities in the United States.

Mallia Will Pitch as Falling Walls Finalist, Heads to BIO-Europe Ahead of Upcoming Product Launch

Erlangen, Germany, October 29, 2025 – Mallia Innovations GmbH, the holding company strategically driving the development and commercialization of biopharmaceutical therapies targeting hair loss and wound healing as well as cosmetic applications for hair growth, and its subsidiaries inform about important events in November.

Falling Walls Science Summit: November 6 – 9 in Berlin, Germany

Prof. Dr. Alexander Steinkasserer, Co-founder and Managing Director of Mallia Therapeutics, will pitch on November 6 as a finalist in the Falling Walls Venture category Science Start-Up.

Mallia Therapeutics has been selected as one of 25 finalists out of over 200 applications across 37 countries at the Falling Walls Science Summit 2025, the international and interdisciplinary forum for global science leaders in Berlin, for its pioneering work at the intersection of immunology and aesthetics. Mallia Therapeutic’s approach translates decades of sCD83 research into novel therapies for hair loss and wound healing. The Company is focusing on the clinical development of novel therapies for patients suffering from androgenetic alopecia or alopecia areata.

The winner, selected by an expert jury, will be awarded the title ‘Science Breakthrough of the Year‘.

BIO-Europe 2025: November 3 – 5 in Vienna, Austria
Dr. Manfred Gröppel, Co-founder and Managing Director of Mallia Innovations, will be on site. Schedule meetings through the partneringONE system or reach out via e-mail.

At the same time, Mallia Aesthetics is gearing up for its upcoming product launch of 8T3 Essentials Hair Serum and 8T3 Essentials Lash & Brow Serum. Both serums are based on a proprietary derivative of the human soluble CD83 protein. Sign up for Mallia’s newsletter to be among the first to find out when the products launch and to receive a discount on your first order.

About sCD83

Soluble CD83 (sCD83) is an immunomodulatory protein that is currently being developed for the topical treatment of hair loss (MAL‑856) and stimulation of hair growth (MAL‑838). The soluble CD83 protein was first identified in 2001 by Mallia co-founder Prof. Steinkasserer. It has anti-inflammatory properties via the induction of resolution of inflammation, which promotes wound healing and induces new hair growth.^[1] In addition, sCD83 has been shown to activate regulatory T cells (Tregs)^[2], which interact directly with hair follicles and can activate them.^[3]Furthermore, sCD83 inhibits cell death of hair follicles and directly activates follicular stem cells, as well as keratin production, thereby stimulating new hair growth. This multimodal mode of action distinguishes sCD83 from other topically applied hair growth agents.

Topically applied, sCD83 can directly reach the hair follicles but does not penetrate through the skin and thus does not enter the bloodstream. The effect is localized, which is a major advantage over systemic treatment options, which can cause severe side effects.

About hair loss

Hormone-related hair loss in men and women (androgenetic alopecia, or AGA) is the most common form of hair loss. Worldwide, more than 70% of men and 50% of women post menopause are affected by androgenetic alopecia. Another 147 million people suffer from immune-related, circular hair loss (alopecia areata, or AA^[4],[5]).

Androgenetic alopecia usually progresses gradually and is due to genetic and hormonal factors. In men, it often leads to a receding hairline and baldness on the top of the head, while in women it causes thinning hair in the parting area. Alopecia areata causes circular hair loss on the scalp, face or other parts of the body. It occurs when the immune system erroneously attacks hair follicles, leading to immune-mediated hair loss.

About Mallia

Mallia Innovations GmbH, based in Erlangen, Germany, is the holding company strategically driving the proprietary development and commercialization of biopharmaceutical therapies and cosmetic applications of the immunomodulatory sCD83 protein, targeting hair growth, hair loss and other dermatological indications, including wound healing.

Mallia Therapeutics GmbH focuses on the clinical development of novel therapies for patients suffering from androgenetic alopecia or alopecia areata, among other conditions. MAL-856 is based on the scientifically proven immunomodulatory mode of action of sCD83, which has been investigated for close to 25 years by Mallia Co‑founder Prof. Dr Alexander Steinkasserer.^[6]

Mallia Aesthetics GmbH focuses on cosmetic applications for the stimulation of hair growth, which are also based on the scientifically validated sCD83 protein. The Company develops Innovative cosmetic products using MAL-838 that will be marketed to specialists and consumers.

For more information, visit www.mallia.com and follow us on LinkedIn and Instagram.

^[1] Royzman, D., Peckert-Maier, K., Stich, L., König, C., Wild, A. B., Tauchi, M., … & Steinkasserer, A. (2022). Soluble CD83 improves and accelerates wound healing by the induction of pro-resolving macrophages. Frontiers in Immunology, 13, 1012647. DOI: 10.3389/fimmu.2022.1012647

^[2] Bock, F., Rössner, S., Onderka, J., Lechmann, M., Pallotta, M. T., Fallarino, F., … & Zinser, E. (2013). Topical application of soluble CD83 induces IDO-mediated immune modulation, increases Foxp3+ T cells, and prolongs allogeneic corneal graft survival. The Journal of Immunology, 191(4), 1965-1975. DOI: 10.4049/jimmunol.1201531

^[3] Ali, N., Zirak, B., Rodriguez, R. S., Pauli, M. L., Truong, H. A., Lai, K., … & Rosenblum, M. D. (2017). Regulatory T cells in skin facilitate epithelial stem cell differentiation. Cell, 169(6), 1119-1129. DOI: 10.1016/j.cell.2017.05.002

^[4] Feinstein, R. P. (2022). Androgenetic alopecia.: https://emedicine.medscape.com/article/1070167-overview

^[5] Mostaghimi, A., Gandhi, K., Done, N., Ray, M., Gao, W., Carley, C., … & Sikirica, V. (2022). All-cause health care resource utilization and costs among adults with alopecia areata: A retrospective claims database study in the United States. Journal of Managed Care & Specialty Pharmacy, 28(4), 426-434: DOI: 10.18553/jmcp.2022.28.4.426

^[6] Lechmann, M., Krooshoop, D. J., Dudziak, D., Kremmer, E., Kuhnt, C., Figdor, C. G., … & Steinkasserer, A. (2001). The extracellular domain of CD83 inhibits dendritic cell–mediated T cell stimulation and binds to a ligand on dendritic cells. The Journal of experimental medicine, 194(12), 1813-1821. DOI: 10.1084/jem.194.12.1813

Immunic to Participate in Industry and Investor Conferences in November

NEW YORK, October 29, 2025 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following industry and investor conferences in November:

• November 3-5: BIO-Europe. Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, Hella Kohlhof, Ph.D., Chief Scientific Officer and Jessica Breu, Vice President Investor Relations and Communications, will participate in partnering activities at this conference in Vienna, Austria. To schedule a meeting, please use the BIO-Europe partneringONE portal or contact Jessica Breu at: jessica.breu@imux.com.
• November 19-20: Dr. Vitt and Jason Tardio, President and Chief Operating Officer of Immunic, will be hosting one-on-one meetings in London in connection with the Jefferies Global Healthcare Conference – London. To schedule a meeting, please contact Jessica Breu at: jessica.breu@imux.com. 

About Immunic, Inc.

Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The company’s lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, for which top-line data is expected to be available by the end of 2026. It has already shown therapeutic activity in phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis and progressive multiple sclerosis. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor-related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease as well as inflammatory bowel disease, Graft-versus-Host-Disease and weight management. IMU-381, which currently is in preclinical testing, is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases. For further information, please visit: www.imux.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to management’s and employee’s participation in industry and investor conferences. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management’s current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs and macroeconomics trends, impacts of the Ukraine – Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, any changes to the size of the target markets for the company’s products or product candidates, the protection and market exclusivity provided by Immunic’s intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned “Risk Factors,” in the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 31, 2025, and in the company’s subsequent filings with the SEC. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release.

Contact Information

Immunic, Inc.
Jessica Breu
Vice President Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com

US IR Contact
Rx Communications Group
Paula Schwartz
+1 917 633 7790
immunic@rxir.com

US Media Contact
KCSA Strategic Communications
Caitlin Kasunich
+1 212 896 1241
ckasunich@kcsa.com

Hamburg, Germany, 29 October 2025:
Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ: EVO) will announce its interim statement for the first nine months 2025 on Wednesday, 05 November 2025.

The Company is going to hold a conference call to discuss the results as well as provide an update on its performance. The conference call will be held in English.

Webcast details

Date:  Wednesday, 05 November 2025

Time:  2.00 pm CET (01.00 pm GMT, 08.00 am EST)

To join the audio webcast and to access the presentation slides, please register via this link.

The on-demand version of the webcast will be available on our website: Financial Publications – Evotec.

Conference call details

To join via phone, please pre-register via this link. You will then receive a confirmation email with dedicated dial-in details such as telephone number, access code and PIN to access the call.

A simultaneous slide presentation for participants dialling in via phone is available under this link.

About Evotec SE
Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure — faster, smarter, and with greater precision.

Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling.

With flexible partnering models tailored to our customers’ needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility.

Through Just – Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability.

With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology.

Evotec’s global team of more than 4,800 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec.

Forward-looking statements
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

For further information, please contact:

Investor Relations

Volker Braun
EVP Head of Global Investor Relations & ESG
Volker.Braun@evotec.com

Dräger with strong demand, noticeable net sales growth and very good earnings performance in the first nine months of 2025

• Order intake significantly increased
• Net sales growth in both divisions and all regions
• EBIT up substantially excluding positive one-off effects in the prior year
• Considerable increase in net sales and earnings in the third quarter
• Annual forecast: net sales and EBIT margin expected to be in the upper half of the range

Lübeck – Drägerwerk AG & Co. KGaA significantly increased its order intake in the first nine months of 2025 thanks to strong demand. At around EUR 2,594 million, order intake exceeded the high prior-year figure by around EUR 174 million (9 months 2024: EUR 2,420.5 million). Net sales increased by around EUR 48 million to around EUR 2,344 million (9 months 2024: EUR 2,295.1 million). At EUR 77.1 million, earnings before interest and taxes (EBIT) did not reach the prior year’s figure (9 months 2024: EUR 80.1 million), but this was mainly due to the positive one-off effects in the prior year. The EBIT margin amounted to 3.3 percent (9 months 2024: 3.5 percent).

“Demand for our ‘Technology for Life’ was significantly higher in the first nine months of 2025 than the prior year’s high level. The last time we had such a strong order intake after three quarters was in our record year 2020,” says Stefan Dräger, Chairman of the Executive Board of Drägerwerk Verwaltungs AG. “Net sales have also increased noticeably. Our earnings have also developed very well. Despite the absence of positive one-off effects and the headwinds from US tariffs and unfavorable exchange rates, we almost matched the prior year’s result. This shows that we are making progress in improving our profitability.”

Order intake significantly increased
In the first nine months of 2025, the Group’s order intake increased by 9.0 percent (net of currency effects) to EUR 2,594.1 million (9 months 2024: EUR 2,420.5 million). This was due to good demand in both divisions and all regions.

In the medical division, order intake rose by 11.6 percent (net of currency effects) to EUR 1,495.5 million (9 months 2024: EUR 1,368.5 million). The main driver was the high demand for our ventilators, anesthesia machines, services, and consumables. In the second quarter, we also received a major multi-year order for hospital infrastructure systems from Mexico.

The safety division continued its order growth. Order intake increased by 5.7 percent (net of currency effects) to EUR 1,098.6 million (9 months 2024: EUR 1,052.1 million). The biggest growth drivers were gas detection, respiratory and personal protection products, and engineered solutions.

Net sales growth in both divisions and all regions
Group net sales rose by 3.7 percent (net of currency effects) to EUR 2,343.5 million in the first nine months of 2025 (9 months 2024: EUR 2,295.1 million). Both divisions grew: the medical division recorded growth of 4.7 percent (net of currency effects) to EUR 1,322.3 million (9 months 2024: EUR 1,285.3 million), while the safety division increased its net sales by 2.4 percent (net of currency effects) to EUR 1,021.2 million (9 months 2024: EUR 1,009.7 million). All regions contributed to growth at both Group and division level.

Earnings up substantially excluding positive one-off effects in the prior year
The gross margin rose by 0.7 percentage points to 45.1 percent in the first nine months of 2025 (9 months 2024: 44.4 percent). The margin improvement in the medical division was stronger than in the safety division.

At EUR 77.1 million, our EBIT did not reach the prior year’s level (9 months 2024: EUR 80.1 million). This was mainly due to positive one-off effects of around EUR 30 million in the prior year: in the second quarter of 2024, Dräger sold a non-strategic business area in the Netherlands and a property in the USA for a total of around EUR 20 million; in addition, a building in Spain was sold for around EUR 10 million in the third quarter of 2024. Currency and tariff effects also had a negative impact on earnings in the first nine months of 2025. Adjusted for these effects, our EBIT would have significantly exceeded the prior year’s figure.

Business development in the third quarter
In the third quarter, order intake increased by 6.9 percent (net of currency effects) to EUR 856.1 million (Q3 2024: EUR 816.2 million). The medical division recorded growth of 5.4 percent (net of currency effects) to EUR 484.7 million (Q3 2024: EUR 468.4 million). In the safety division, order intake increased by 8.8 percent (net of currency effects) to EUR 371.4 million (Q3 2024: EUR 347.8 million).

Dräger’s net sales increased significantly by 10.1 percent (net of currency effects) to EUR 833.3 million (Q3 2024: EUR 774.6 million). Both divisions and all regions recorded growth. The gross margin increased by 2.1 percentage points to 45.6 percent (Q3 2024: 43.5 percent). EBIT more than doubled to EUR 56.7 million (Q3 2024: EUR 24.4 million) despite the negative effects mentioned above. The EBIT margin also increased significantly by 3.7 percentage points to 6.8 percent (Q3 2024: 3.1 percent).

Annual forecast: net sales and EBIT margin expected to be in the upper half of the range
For the current fiscal year, Dräger now tends to expect net sales growth of 3.0 to 5.0 percent net of currency effects (previously 1.0 to 5.0 percent net of currency effects) and an EBIT margin of 4.5 to 6.5 percent (previously 3.5 to 6.5 percent).

“The excellent order development and the increasing sales momentum make us optimistic for the further course of business this year,” says Stefan Dräger.

Further information is available in the financial report at www.draeger.com.

Disclaimer
This press release contains statements on the future development of Dräger Group. These forward-looking statements are based on the current expectations, presumptions, and forecasts of the Executive Board as well as the information available to date. They were compiled to the best of the company’s knowledge. Dräger does not provide any warranty nor assume any responsibility for the future developments and results described above. These are dependent on a number of factors. They entail various risks and contingencies outside of the company’s influence and are based on assumptions which could prove to be incorrect. Dräger does not assume any responsibility for updating the forward-looking statements contained in this report. This does not infringe any legal stipulations on the adjustment of forecasts. Information on the financial indicators used (incl. alternative performance measures) can be found on our corporate website www.draeger.com in our Investor Relations section.